A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 2,701–2,800 of 3,965
Juliá-Serdà, G., Navarro-Esteva, J., Doreste-Salgado, L., et al. (2024) · Cureus · doi:10.7759/cureus.57307 · Cited by 3
Potential therapeutic targets of fibrosis in inflammatory rheumatic diseases
Jiang, S., Desmarais, J., Chu, C., & Zhu, J. (2024) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2024.101945 · Cited by 3
Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease
Perrotta, F., Zamparelli, S. S., D’Agnano, V., Montella, A., Fomez, R., Pagliaro, R., Schiattarella, A., Cazzola, M., Bianco, A., & Mariniello, D. F. (2024) · Biomedicines · doi:10.3390/biomedicines12071384 · Cited by 4
Villar, A., Rodríguez‐Nieto, M. J., Cano-Jiménez, E., Ortiz, A. R., Morros, M., Ramon, A., & Armengol, S. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03186-4 · Cited by 3
Branco, H., Rodrigues, C. A., Oliveira, J., Mendes, N. M., Antunes, C., Amorim, I., Santos, L. L., Vasconcelos, M. H., & Xavier, C. P. R. (2024) · International Journal of Cancer · doi:10.1002/ijc.35276 · Cited by 3
Lamellarin D Acts as an Inhibitor of Type I Collagen Production
Okuno, D., Sakamoto, N., Hayashi, H., et al. (2025) · ChemMedChem · doi:10.1002/cmdc.202401001 · Cited by 3
Ex vivo removal of pro-fibrotic collagen and rescue of metabolic function in human ovarian fibrosis
del Valle, J. S., van Helden, R. W. J., Moustakas, I., Fu, W. E., Asseler, J. D., Metzemaekers, J., Pilgram, G. S. K., Mummery, C. L., van der Westerlaken, L. A. J., van Mello, N. M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112020 · Cited by 5
Non-Pharmacological Management of Idiopathic Pulmonary Fibrosis
Mullholand, J. B., GROSSMAN, C. E., & Perelas, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041317 · Cited by 4
“Despite the progress made in understanding its pathogenesis, the therapies available to date have only been shown to reduce the rate of disease progression without a major effect on symptom burden or quality of life [2,3].”
The Intersection between Immune System and Idiopathic Pulmonary Fibrosis—A Concise Review
Liu, H., Cui, H., & Liu, G. (2025) · Fibrosis · doi:10.70322/fibrosis.2025.10004 · Cited by 7
Air trapping in patients with idiopathic pulmonary fibrosis: a retrospective case—control study
Kim, T. H., Kim, M. A., Youn, S. H., Kwon, Y. S., Kim, H. J., Park, J. S., & Park, S. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-91060-6 · Cited by 3
Zhang, Y., Liu, Y., Li, X., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119550 · Cited by 3
Criner, R. N., Naranjo, M., D’Alonzo, G. E., & Weaver, S. (2025) · Biomedicines · doi:10.3390/biomedicines13040808 · Cited by 4
“The 2014 randomized, placebo-controlled, phase 3 ASCEND clinical trial compared thrice-daily oral medication pirfenidone, a transforming growth factor-ß inhibitor proposed to inhibit fibroblast proliferation and collagen synthesis, to placebo in IPF patients [21,22].”
InfluentialProgress through Persistence — Turning the Page in Pulmonary Fibrosis Clinical Trials
Lee, J. S. (2025) · New England Journal of Medicine · doi:10.1056/nejme2505760 · Cited by 4
Use of Spirometry in Pulmonary Function Evaluation
Mohning, M. P., & Krefft, S. D. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.04.001 · Cited by 4
Moua, T., & Benzo, R. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2539540 · Cited by 4
Zhao, Q., Mo, N., Li, R., Wei, T. T., Xu, W., Wang, J., Li, S., Zhu, H., & Miao, G. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03804-9 · Cited by 3
Halder, D., Khan, M. S., Sue, T., Ali, M., Jahan, U. M. S., Atiquzzaman, M., Khatun, M., Islam, M. K., Keya, R. B., Hasan, A., et al. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110867 · Cited by 3
Fan, L., Shetty, R. S., Dao, H. M., Balnadupete, A., Somasundram, B., Bhagavath, A. K., Kongara, A., Tang, H., Citrin, D. E., Williams, R. O., et al. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00295.2024 · Cited by 3
Zhang, W., Li, L., Li, W., Wang, J., Gao, X.-F., Zhang, S., Zhang, M., Jiang, S., & Li, W. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120448 · Cited by 11
Fang, Y., Hsieh, Y.-A., Chen, Y., Chiu, Y.-C., Lin, Y., Huang, K., Huang, Y., Wei, Y., Huang, C., & Fu, P. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03890-9 · Cited by 3
Wong, A. W., Marinescu, D.-C., Johannson, K. A., Marcoux, V. S., Fisher, J. H., Assayag, D., Manganas, H., Kolb, M. R. J., Ryerson, C. J., & Guler, S. A. (2025) · European Respiratory Journal · doi:10.1183/13993003.01533-2025 · Cited by 4
Idiopathic fibrotic lung disease at a university hospital setting: management and prognostic factors
Rad, P., Karlsson, C.-A., & Janson, C. (2015) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v2.26915 · Cited by 3
Not yet known side effects of pirfenidone in the treatment of idiopathic pulmonary fibrosis?
Campainha, S., Nogueira, C., Costa, F. C., et al. (2015) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2015.10.002 · Cited by 3
Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis: More than a Gut Feeling?
Wuyts, W. A., & Collard, H. R. (2016) · Respiration · doi:10.1159/000443183 · Cited by 3
Spagnolo, P., Sverzellati, N., & Rossi, G. (2016) · Respirology · doi:10.1111/resp.12824 · Cited by 3
Cordeiro, C. R., Alfaro, T. M., Freitas, S., & Cemlyn-Jones, J. M. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10009414 · Cited by 3
Pirfenidone-induced hyponatraemia: insight in mechanism, risk factor and management
Silhan, L. L., Galiatsatos, P., Corwine, J., & Danoff, S. K. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-222734 · Cited by 3
Does pirfenidone have anticancer effects in patients with idiopathic pulmonary fibrosis?
Tanino, Y. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2017.12.001 · Cited by 3
Idiopathic pulmonary fibrosis: time for greater expectations?
Wuyts, W. A., & Cottin, V. (2018) · European Respiratory Journal · doi:10.1183/13993003.01312-2018 · Cited by 3
Pericytes and T Cells in Lung Injury and Fibroproliferation
Birbrair, A., Prazeres, P. H. D. M., Files, D. C., & Delbono, O. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_7 · Cited by 4
Wolters, P. J., & Cottin, V. (2019) · European Respiratory Journal · doi:10.1183/13993003.00283-2019 · Cited by 3
Casillo, V., Cerri, S., Ciervo, A., Stendardo, M., Manzoli, L., Flacco, M. E., Manno, M., Bocchino, M., Luppi, F., & Boschetto, P. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0930-7 · Cited by 3
Idiopathic pulmonary fibrosis: accurate diagnosis and early treatment
Morais, A. (2019) · Jornal Brasileiro de Pneumologia · doi:10.1590/1806-3713/e20190353 · Cited by 3
Update in Imaging of Idiopathic Pulmonary Fibrosis
Kaproth-Joslin, K. A., Croake, M. F., & Hobbs, S. (2020) · Advances in Clinical Radiology · doi:10.1016/j.yacr.2020.04.004 · Cited by 3
Sgalla, G., Mari, P., & Richeldi, L. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3243 · Cited by 2
Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?
Wongkarnjana, A., & Ryerson, C. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00894-2020 · Cited by 3
Management of idiopathic pulmonary fibrosis: A survey of Canadian respirologists
Fidler, L. M., Burns, K. E. A., Singer, L. G., Kiss, A., Shapera, S., & Stanbrook, M. B. (2020) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2020.1767524 · Cited by 3
Guellec, S. L., Allimonnier, L., Heuzé‐Vourc'h, N., Cabrera, M., Ossant, F., Pourchez, J., Vecellio, L., & Plantier, L. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.01022 · Cited by 4
Investigation of telomere related gene mutations in idiopathic pulmonary fibrosis
Yıldırım, H., Yildiz, P., & Coşkunpınar, E. M. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05861-1 · Cited by 4
Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases
Kang, E. H., & Song, Y. W. (2021) · Pharmaceuticals · doi:10.3390/ph14030251 · Cited by 6
Karayama, M., Aoshima, Y., Yasui, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87452-z · Cited by 3
Resistance Training for Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis
Vainshelboim, B., & MYERS, J. N. (2021) · Translational Medicine and Exercise Prescription · doi:10.53941/tmep.v1i1.34 · Cited by 2
Special considerations for pulmonary rehabilitation in conditions other than COPD
Cavalheri, V., Vainshelboim, B., Evans, R. A., da Fontoura, F. F., & Lee, A. L. (2021) · European Respiratory Society eBooks · doi:10.1183/2312508x.10018220 · Cited by 3
Beyond TGFβ1 - novel treatment strategies targeting lung fibrosis
Sim, C., Lamanna, E., Cirnigliaro, F., & Lam, M. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106090 · Cited by 3
Çoşkun, F., Çilli, A., Hanta, İ., Sevinç, C., Ödemiş, A., & Ursavaş, A. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2102-262 · Cited by 3
Villeneuve, T., Prévôt, G., Lintz, F., Mourin, G., Ferry, G., Bousquet, E., Perelroizen, H., Boghanim, T., Faviez, G., Noël-Savina, É., et al. (2021) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2021.07.004 · Cited by 3
Antifibrotic therapies for idiopathic pulmonary fibrosis
Akbar, I., Mann, J., Niewodowski, D., Mackintosh, J. A., Glaspole, I., & Barnes, H. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015076 · Cited by 4
Self-citationManzetti, G. M., Hosein, K., Cecchini, M. J., Kwan, K. F., Abdelrazek, M., Zompatori, M., Rogliani, P., & Mura, M. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01753-7 · Cited by 3
Tseng, C.-M., Chen, M.-Y., Kao, C.-Y., & Tao, C.-W. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000719 · Cited by 5
Fibrose pulmonaire idiopathique : actualisation des recommandations pratiques
Cottin, V., Bonniaud, P., Cadranel, J. L., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., & Crestani, B. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.03.004 · Cited by 4
Kostorz‐Nosal, S., Jastrzębski, D., Żebrowska, A., Bartoszewicz, A., & Ziora, D. I. (2022) · Medicina · doi:10.3390/medicina58111551 · Cited by 3
Taweesedt, P. T., Lertjitbanjong, P., Eksombatchai, D., Charoenpong, P., Moua, T., Thongprayoon, C., Tangpanithandee, S., & Petnak, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020655 · Cited by 5
Ngo, H. G., NAIR, G. B., & Al‐Katib, S. (2023) · Clinical Imaging · doi:10.1016/j.clinimag.2023.03.004 · Cited by 3
Health Care Disparities in Pulmonary Fibrosis—Time to Move the Needle Forward
Mageto, Y. N. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.2442 · Cited by 3
Lewandowska, K. B., Sobiecka, M., Boros, P. W., Dybowska, M., Barańska, I., Jędrych, M. E., Gładzka, A., Tomkowski, W. Z., & Szturmowicz, M. (2023) · Diagnostics · doi:10.3390/diagnostics13061109 · Cited by 4
Pulmonary Alveolar Proteinosis Syndrome
O’Callaghan, M., McCarthy, C., & Trapnell, B. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_22 · Cited by 3
Feshchenko, Y. I., Gavrysyuk, V. K., Горовенко, Н. Г., Dziublyk, O., Pertseva, T. O., Ostrovsky, M. M., Basanets, A. V., Bychenko, O. V., Dziublyk, Y. O., Konopkina, L., et al. (2023) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2023-31-1-5-33 · Cited by 4
Lybéris, P., Verri, G., Solidoro, P., Femia, F., PEROTTI, C., Limerutti, G., Delsedime, L., Beffa, E. D., Papotti, M. G., Ruffini, E., et al. (2023) · Minerva Surgery · doi:10.23736/s2724-5691.23.09948-3 · Cited by 3
Kim, K.-I., Hossain, R., Li, X., Lee, H. J., & Lee, H. J. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2023.056 · Cited by 3
Clinical significance of high monocyte counts for the continuous treatment with nintedanib
Tsuneyoshi, S., Zaizen, Y., Tominaga, M., Matama, G., Umemoto, S., Ohno, S., Takaki, R., Yano, R., Murotani, K., Okamoto, M., et al. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02536-y · Cited by 4
Hollmén, M., Bromilow, T., Smith, A. B., Mealing, S., Lewis, D., Galvin, L., Jones, S., Pacheco, L., Soulard, S., & Froidure, A. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s408857 · Cited by 3
Fang, H., Dong, T., Han, Z., Li, S., Liu, M., Liu, Y., Yang, Q., Fu, M., & Zhang, H. (2023) · International Journal of COPD · doi:10.2147/copd.s426763 · Cited by 6
Mandovra, N. P., Vaidya, P. J., Shah, R., Nighojkar, A., Chavhan, V. B., Lohiya, A., Leuppi, J. D., Taegtmeyer, A. B., & Chhajed, P. N. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206513 · Cited by 4
Jang, J. H., Ko, J., Jung, S. Y., Kim, D.-W., Oh, J. H., Kim, T. J., Park, J. H., Choi, M., & Lee, J. H. (2023) · Life · doi:10.3390/life13122318 · Cited by 6
Huang, T., Wei, S., Kuo, H.-I., Hou, H.-Y., Kuo, C., Tseng, Y., Lin, S., & Wu, C. (2024) · Biomedicines · doi:10.3390/biomedicines12020402 · Cited by 3
Li, S., Chen, W., Zhong, Y., Qi, D., Tan, Y., Zhang, R., & Wang, D. (2024) · Materials & Design · doi:10.1016/j.matdes.2024.112811 · Cited by 4
Ash, S. Y., Doyle, T. J., Choi, B., Estépar, R. S. J., Castro, V., Enzer, N. A., Kalhan, R., Liu, G. Y., Bowler, R. P., Wilson, D. O., et al. (2024) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-002219 · Cited by 3
Gunsalus, P. R., Rose, J., Lehr, C. J., Valapour, M., & Dalton, J. E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296839 · Cited by 4
A modular simulation framework for organ allocation
Rose, J., Gunsalus, P. R., Lehr, C. J., Swiler, M. F., Dalton, J. E., & Valapour, M. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.04.063 · Cited by 6
Cuesta, V. M. M., Meñaca, A. M., González-Fernández, Á., Fernandez, D. I., Tello-Mena, S., Izquierdo‐Cuervo, S., Fernández-Rozas, S., Alonso‐Lecue, P., & Martínez, J. M. C. (2024) · Heart & Lung · doi:10.1016/j.hrtlng.2024.04.022 · Cited by 3
Ma, L., Liu, C., Zhao, Y., Liu, M., Liu, Y., Zhang, H., Yang, S., An, J., Tian, Y., Cao, Y., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1374669 · Cited by 3
Adewale, A. T., Sharma, S., Mouawad, J. E., Nguyen, X.-X., Bradshaw, A. D., & Feghali‐Bostwick, C. A. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.06.002 · Cited by 3
Han, M., Huo, B., Hu, G., Zhang, X., Cui, G., Wu, W., Mi, N., Zhang, S., Jin, J., Lu, X., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1414066 · Cited by 3
Kang, M., Gupta, S., Tu, Y.-H., Raimundo, K., Patel, A. M., & Flaherty, K. R. (2024) · CHEST Pulmonary · doi:10.1016/j.chpulm.2024.100082 · Cited by 4
m6A methyltransferase ZC3H13 improves pulmonary fibrosis in mice through regulating Bax expression
Guan, J., Yin, L., Huang, Q., Chen, J., Liu, H., & Li, J. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114255 · Cited by 5
Enomoto, N., Nakai, S., Yazawa, S., Mochizuka, Y., Fukada, A., Tanaka, Y., Naoi, H., Inoue, Y., Yasui, H., Karayama, M., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02982-0 · Cited by 4
Rautajoki, T., Rantala, H. A., Sutinen, E., Saarto, T. H., Rajala, K., Pesonen, I., Hollmén, M., Myllärniemi, M., & Lehto, J. T. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03303-3 · Cited by 7
Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis
Spagnolo, P., Tonelli, R., Mura, M., Reisman, W. M., Sotiropoulou, V., & Tzouvelekis, A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2462592 · Cited by 3
Jing, F., Wang, W., Ke, J., Huang, T., Jiang, B., Qiu, Q., Huang, J., Zhan, S., Zhang, W., Wu, H., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1508276 · Cited by 4
Wan, Y., Li, W., Zhu, H., Ai, S., & Lin, W. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00183h · Cited by 3
Cough in idiopathic pulmonary fibrosis: what is new
da Silva, M. A. C., Rolo, R., Catarata, M. J., et al. (2025) · Breathe · doi:10.1183/20734735.0176-2024 · Cited by 3
Lin, F., Lin, K., Li, D., Kong, W., Zhuang, J., He, W., Wei, X., Xiao, T., Zu, H., Zhang, Z., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03696-9 · Cited by 3
Todd, J. L., Neely, M. L., Hellkamp, A. S., Culver, D. A., Oldham, J. M., Li, P., Patel, D. C., Palmer, S. M., & on behalf of the IPF-PRO Registry investigators (2025) · Lung · doi:10.1007/s00408-025-00845-z · Cited by 6
Signal Processing Applications Of Free Probability Theory
Ryan, Ø., & Debbah, M. A. (2007) · HAL (Le Centre pour la Communication Scientifique Directe) · doi:10.5281/zenodo.40444 · Cited by 3
Advances in CT Diagnosis of UIP and IPF
Thiessen, R., Fenwick, J. L., & Lynch, D. A. (2018) · Seminars in Roentgenology · doi:10.1053/j.ro.2018.12.001 · Cited by 5
Choi, W.-I. (2021) · Precision and Future Medicine · doi:10.23838/pfm.2020.00205 · Cited by 3
Fibrosis on a Chip for Screening of Anti-Fibrosis Drugs
Asmani, M., & Zhao, R. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1382-5_19 · Cited by 6
Pérez, E. R. F., Crooks, J., Swigris, J. J., Solomon, J. J., Mohning, M. P., Huie, T. J., Koslow, M., Lynch, D. A., Groshong, S. D., & Fier, K. (2021) · ERJ Open Research · doi:10.1183/23120541.00054-2021 · Cited by 4
Self-citationKelly, J. H. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101186 · Cited by 4
“The two FDA approved drugs for its treatment, nintedanib and pirfenidone, only slow progression but cannot reverse existing disease [26,27].”
BackgroundThe Syndrome of Combined Pulmonary Fibrosis and Emphysema
Cottin, V., & Cordier, J.-F. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2401-6_22 · Cited by 4
Current and Emerging Approaches to the Diagnosis and Treatment of Crohn's Disease Strictures.
Lee, B., Dane, B. R., & Katz, S. (2022) · PubMed Central · Cited by 3
Shen, L. (2019) · Archives of Rheumatology · doi:10.5606/archrheumatol.2020.7381 · Cited by 3
Luo, M., & Wang, J. (2022) · Respirology Case Reports · doi:10.1002/rcr2.1032 · Cited by 2
Avdeev, S. N., Ilkovich, M. M., Terpigorev, S. A., Moiseev, S. V., & Tyurin, I. E. (2023) · Life · doi:10.3390/life13020483 · Cited by 5
On Bedrosian Condition In Application To Chirp Sounds
Hermanowicz, E. (2007) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.40452 · Cited by 3
Jenkins, G. R. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-206209 · Cited by 3
Personalizing Therapy in Idiopathic Pulmonary Fibrosis: A Glimpse of the Future?
Kropski, J. A., Lawson, W. E., & Blackwell, T. S. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201509-1789ed · Cited by 3
Emerging therapies for pancreatic ductal carcinoma
Falcone, R., Davis, P. J., Stain, S. C., & Mousa, S. A. (2016) · Journal of Solid Tumors · doi:10.5430/jst.v6n1p65 · Cited by 3
“[31] The drug works by reducing fibroblast proliferation, TGF-beta induced alpha-smooth muscle actin, pro-collagen mRNA, and protein.”
BackgroundPanorama actual de la fibrosis pulmonar idiopática en México
Barreto-Rodríguez, J. O., Mejía, M. E., & Buendía-Roldán, I. (2015) · NCT Neumología y Cirugía de Tórax · doi:10.35366/63377 · Cited by 3
Targeted treatment of idiopathic pulmonary fibrosis: one step at a time
Richeldi, L. (2016) · European Respiratory Journal · doi:10.1183/13993003.00389-2016 · Cited by 3
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.